Please login to the form below

Not currently logged in
Email:
Password:

IRX Therapeutics appoints Luba Greenwood to its board

She recently served as venture partner at Colt Ventures

Clinical-stage company IRX Therapeutics has appointed Luba Greenwood to its board of directors.

Her career has seen her gain significant pharmaceutical and biotechnology industry expertise, including building technology companies and providing strategic counsel to corporations.

Mark Leuchtenberger, president and chief executive officer, IRX Therapeutics, said: “Luba is a proven and respected leader in the life science sector.

“She has excelled as an investor, business development professional, lawyer and corporate strategist.”

Her career has spanned leadership roles in venture investing, business development, mergers and acquisitions, law, consulting and operations.

Greenwood most recently served as venture partner at Colt Ventures, and led business development strategy for Pronutria.

Prior to that, she served as senior mergers and acquisitions counsel at Pfizer.

She said: “I look forward to working with the management team as they explore the potential to reduce immune suppression in the tumour microenvironment with IRX-2.”

6th December 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CMR

Specialising in medical device market research, our approach is people-centric and we thrive on making connections with clients and research...

Latest intelligence

Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist
...
Erik
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...

Infographics